Skip to content

Microbiological and Biochemical Profiling of Amniotic Fluid in Women With Short Cervix or Premature Rupture of Membranes

Microbiological and Biochemical Profiling of Amniotic Fluid in Women With Short Cervix or Premature Rupture of Membranes

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07792083
Acronym
CIPRO
Enrollment
300
Registered
2026-08-28
Start date
2025-12-23
Completion date
2030-12-01
Last updated
2026-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PROM, Preterm (Pregnancy), Short Cervix

Brief summary

This study aims at assessing the efficacy, reliability, and clinical impact of Amniotic Fluid analysis by Nanopore DNA sequencing compared to the standard bacterial cultures in detecting intra-amniotic/inflammation in patients with short cervix or premature rupture of membranes.

Interventions

OTHERamniotic fluid collection

Amniotic fluid by amniocentesis or by sterile cervical aspiration via the vagina

Sponsors

Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Singleton pregnancy; * Age \> 18 years; * Pregnant women diagnosed with cervical incompetence (via ultrasound criteria) with cervical length \<24 mm, before 24 weeks of gestational age, with intact amniotic membranes and absence of uterine contractions; * Pregnant women diagnosed with p-PROM (via clinical criteria and/or with a qualitative immunoassay vaginal test) before 34 weeks of gestational age; * Healthy pregnant women with uncomplicated obstetric history who underwent amniocentesis to exclude chromosomal abnormalities; * Informed consent to participate in the study.

Exclusion criteria

* Multiple pregnancy; * Patients with contraindications to amniocentesis, including severe bleeding disorders or placenta previa; * Patients with known fetal anomalies incompatible with life; * Patients with sepsis or clinical diagnosis of chorioamnionitis;

Design outcomes

Primary

MeasureTime frameDescription
Microbiological analysis of amniotic fluid by next generation analysisFrom date of enrollment to the end of pregnancy (up to 9 months)Presence and concentrations of bacteria in amniotic fluid

Countries

Italy

Contacts

CONTACTChiara Tersigni
chiara.tersigni@policlinicogemelli.it+390630157546
PRINCIPAL_INVESTIGATORChiara Tersigni

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 29, 2026